Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
ABX 51.95 −0.5% TTS 2.50 +0.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.68 +9.0% TUNG 1.72 +1.8% LGO 1.00 −3.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.43 +0.0% SGZ 0.045 +0.0% S 0.150 +25.0% GRSL 0.315 −1.6% DEX 0.390 +1.3% WMS 0.040 +0.0% EMPR 0.830 +1.2% ABX 51.95 −0.5% TTS 2.50 +0.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.68 +9.0% TUNG 1.72 +1.8% LGO 1.00 −3.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.43 +0.0% SGZ 0.045 +0.0% S 0.150 +25.0% GRSL 0.315 −1.6% DEX 0.390 +1.3% WMS 0.040 +0.0% EMPR 0.830 +1.2%
Financings Routine −

Betterlife arranges $2-million debenture financing

Pre-revenue psychedelic-adjacent biotech secures critical $2M lifeline amid severe liquidity crunch.

By The Northwire Desk — AI Analysis Jun 15, 2026 · 16:36 BETR · 0.07 Betterlife Pharma Inc
Executive Summary
  • Betterlife Pharma Inc. announced a $2 million CAD convertible debenture private placement.
  • The debenture carries a 10% annual interest rate and matures one year from closing.
  • Conversion price is set at $0.06 per unit, below the recent trading range.
  • Each unit includes one common share and one warrant exercisable at $0.10 for three years.
  • A director/insider intends to subscribe for the full amount, subject to a 19.9% ownership cap.
  • Proceeds are designated for completing IND-enabling studies for BETR-001 and general working capital.
  • Anticipated closing is June 25, 2026, with a 4-month and 1-day statutory hold period.
Material Impact
  • The financing provides essential runway to complete IND-enabling work and file for an Investigational New Drug application, aligning with management's previously stated 2H 2026 timeline.
  • The $0.06 conversion price represents a discount to the current market price of $0.07, introducing immediate dilution for existing shareholders.
  • The issuance of warrants at $0.10 adds further potential overhang, as these warrants will be exercisable for three years.
  • Given the company's critically low cash balance ($12,570 CAD), this capital raise is a survival mechanism rather than a growth accelerator.
  • The related-party nature of the subscription mitigates execution risk but concentrates ownership among insiders.
BETR · Price
Company Overview
  • Betterlife Pharma Inc. is a pre-revenue biotechnology company focused on neurological and antiviral therapeutics.
  • Lead candidate BETR-001 is a proprietary, non-hallucinogenic LSD derivative (2-bromo-LSD) targeting neurological pain, cluster headaches, migraine, and traumatic brain injury.
  • The company holds a USPTO composition-of-matter patent and a pending method-of-use patent covering neurological disorders through approximately 2042.
  • Secondary pipeline includes recombinant interferon-based therapies (MM-001/MM-003) for viral infections, though development paths are being reassessed.
  • The company has engaged YAFO Capital for strategic partnerships in Greater China.
Read the original news release →

More from Betterlife Pharma Inc

Jun 25, 2026 · 08:01

Pre-revenue psychedelic-adjacent biotech secures CAD $2M financing and GMP manufacturing partner for BETR-001 IND filing.

M&A / Property Jun 22, 2026 · 08:01

BetterLife Pharma Secures CAD $2 Million in New Capital to Complete BETR-001 FDA IND Filing

Financings Apr 10, 2026 · 16:29

BETR-001 IND Filing Delayed to 2H 2026 as Company Extends Debt Maturity

Financings Apr 08, 2026 · 17:22

“Tiny $500K private placement adds cash but deepens dilution for BETR‑001 pipeline”

Financings Apr 02, 2026 · 18:15

Betterlife issues 2.15M shares in debenture conversion

Financings Dec 11, 2025 · 16:58

Betterlife hires YAFO as adviser in Greater China

M&A / Property